Considering that in 30% of GC cases, intra-tumoral HER2 expression alters due to HER2-based targeted therapies (13), the timely monitoring of HER2 expression during treatment for fine-tuning regimens is critical, but this is currently impossible. This evidence concerns the gene ERBB2 and gastric cancer.